Compare EXTR & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXTR | TLX |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1999 | N/A |
| Metric | EXTR | TLX |
|---|---|---|
| Price | $14.15 | $6.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $21.20 | $21.00 |
| AVG Volume (30 Days) | ★ 2.0M | 174.1K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $1,140,067,000.00 | N/A |
| Revenue This Year | $13.15 | N/A |
| Revenue Next Year | $7.52 | N/A |
| P/E Ratio | ★ $141.65 | $150.33 |
| Revenue Growth | ★ 2.05 | N/A |
| 52 Week Low | $10.11 | $6.28 |
| 52 Week High | $22.89 | $20.00 |
| Indicator | EXTR | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 33.11 |
| Support Level | $13.98 | $6.28 |
| Resistance Level | $14.72 | $6.63 |
| Average True Range (ATR) | 0.63 | 0.23 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 10.38 | 7.02 |
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.